EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 86 (2024) BIO Web Conf., 86 (2024) 01028 References
Open Access
Issue
BIO Web Conf.
Volume 86, 2024
International Conference on Recent Trends in Biomedical Sciences (RTBS-2023)
Article Number 01028
Number of page(s) 10
DOI https://doi.org/10.1051/bioconf/20248601028
Published online 12 January 2024
  • Parent, Martin, and André Parent. 2010. “Substantia Nigra and Parkinson’s Disease: A Brief History of Their Long and Intimate Relationship.” Canadian Journal of Neurological Sciences 37 (3): 313–19. [CrossRef] [PubMed] [Google Scholar]
  • Trinh, Joanne, Florentine M J Zeldenrust, Jana Huang, Meike Kasten, Susen Schaake, Sonja Petkovic, Harutyun Madoev, et al. 2018. “Genotype-Phenotype Relations for the Parkinson’s Disease Genes SNCA, LRRK2, VPS35: MDSGene Systematic Review.” Movement Disorders 33 (12): 1857–70. [CrossRef] [PubMed] [Google Scholar]
  • Schulz-Schaeffer, Walter J. 2010. “The Synaptic Pathology of α-Synuclein Aggregation in Dementia with Lewy Bodies, Parkinson’s Disease and Parkinson’s Disease Dementia.” Acta Neuropathologica 120 (2): 131–43. [CrossRef] [PubMed] [Google Scholar]
  • Simon, David K, Caroline M Tanner, and Patrik Brundin. 2020. “Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.” Clinics in Geriatric Medicine 36 (1): 1–12. [CrossRef] [PubMed] [Google Scholar]
  • Hirsch, Etienne C, Sheela Vyas, and Stéphane Hunot. 2012. “Neuroinflammation in Parkinson’s Disease.” Parkinsonism & Related Disorders 18: S210–12. [CrossRef] [PubMed] [Google Scholar]
  • Halliday, Glenda Margaret, and Heather McCann. 2010. “The Progression of Pathology in Parkinson’s Disease.” Annals of the New York Academy of Sciences 1184 (1): 188–95. [CrossRef] [PubMed] [Google Scholar]
  • Hallett, Mark. 2012. “Parkinson’s Disease Tremor: Pathophysiology.” Parkinsonism & Related Disorders 18: S85–86. [CrossRef] [PubMed] [Google Scholar]
  • Pan-Montojo, Francisco, and Heinz Reichmann. 2014. “Considerations on the Role of Environmental Toxins in Idiopathic Parkinson’s Disease Pathophysiology.” Translational Neurodegeneration 3 (1): 1–13. [CrossRef] [PubMed] [Google Scholar]
  • Rocha Emily, M, Matthew T Keeney, Roberto Di Maio, Briana R De Miranda, and J Timothy Greenamyre. 2022. “LRRK2 and Idiopathic Parkinson’s Disease.” Trends in Neurosciences 45 (3): 224–36. [CrossRef] [PubMed] [Google Scholar]
  • Filippi, Massimo, Sarasso Elisabetta, Noemi Piramide, and Federica Agosta. 2018. “Chapter Fourteen - Functional MRI in Idiopathic Parkinson’s Disease.” In Imaging in Movement Disorders: Imaging Methodology and Applications in Parkinson’s Disease, edited by Marios B T - International Review of Neurobiology Politis, 141:439–67. Academic Press. [Google Scholar]
  • Hayes, Michael T. 2019. “Parkinson’s Disease and Parkinsonism.” The American Journal of Medicine 132 (7): 802–7. https://doi.org/https://doi.org/10.1016/j.amjmed.2019.03.001. [CrossRef] [PubMed] [Google Scholar]
  • Morley, James F, Stephanie M Pawlowski, Adhithi Kesari, Ivy Maina, Alexander Pantelyat, and John E Duda. 2014. “Motor and Non-Motor Features of Parkinson’s Disease That Predict Persistent Drug-Induced Parkinsonism.” Parkinsonism & Related Disorders 20 (7): 738–42. [CrossRef] [PubMed] [Google Scholar]
  • Shin, Hae-Won, and Sun Ju Chung. 2012. “Drug-Induced Parkinsonism.” Journal of Clinical Neurology 8 (1): 15–21. [CrossRef] [PubMed] [Google Scholar]
  • Thanvi, B, and S Treadwell. 2009. “Drug Induced Parkinsonism: A Common Cause of Parkinsonism in Older People.” Postgraduate Medical Journal 85 (1004): 322–26. [CrossRef] [PubMed] [Google Scholar]
  • Raza, Chand, and Rabia Anjum. 2019. “Parkinson’s Disease: Mechanisms, Translational Models and Management Strategies.” Life Sciences 226: 77–90. [CrossRef] [PubMed] [Google Scholar]
  • Cicchetti, Francesca, Janelle Drouin-Ouellet, and Robert E Gross. 2009. “Environmental Toxins and Parkinson’s Disease: What Have We Learned from Pesticide-Induced Animal Models?” Trends in Pharmacological Sciences 30 (9): 475–83. [CrossRef] [PubMed] [Google Scholar]
  • Martinez, Terina N, and J Timothy Greenamyre. 2012. “Toxin Models of Mitochondrial Dysfunction in Parkinson’s Disease.” Antioxidants & Redox Signaling 16 (9): 920–34. [CrossRef] [PubMed] [Google Scholar]
  • Bové, Jordi, Delphine Prou, Céline Perier, and Serge Przedborski. 2005. “Toxin-Induced Models of Parkinson’s Disease.” NeuroRx 2 (3): 484–94. [CrossRef] [PubMed] [Google Scholar]
  • Goldman, Samuel M. 2014. “Environmental Toxins and Parkinson’s Disease.” Annual Review of Pharmacology and Toxicology 54: 141–64. [CrossRef] [PubMed] [Google Scholar]
  • Tsakanikas, Diamanto, and Norman Relkin. 2007. “Normal Pressure Hydrocephalus.” In Seminars in Neurology, 27:58–65. Copyright© 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue. [Google Scholar]
  • Nikaido, Yasutaka, Toshihiro Akisue, Yoshinaga Kajimoto, Adam Tucker, Yuki Kawami, Hideyuki Urakami, Yuka Iwai, Hisatomo Sato, Tadayuki Nishiguchi, and Tetsuya Hinoshita. 2018. “Postural Instability Differences between Idiopathic Normal Pressure Hydrocephalus and Parkinson’s Disease.” Clinical Neurology and Neurosurgery 165: 103–7. [CrossRef] [PubMed] [Google Scholar]
  • Hart, Madeline, Joshua Conrad, Emma Barrett, Kaitlyn Legg, Gabrielle Ivey, Peter H U Lee, Yun C Yung, and Joon W Shim. 2023. “X-Linked Hydrocephalus Genes: Their Proximity to Telomeres and High A+ T Content Compared to Parkinson’s Disease.” Experimental Neurology 366: 114433. [CrossRef] [PubMed] [Google Scholar]
  • Hattori, T, T Yuasa, S Aoki, R Sato, H Sawaura, T Mori, and H Mizusawa. 2011. “Altered Microstructure in Corticospinal Tract in Idiopathic Normal Pressure Hydrocephalus: Comparison with Alzheimer Disease and Parkinson Disease with Dementia.” American Journal of Neuroradiology 32 (9): 1681–87. [CrossRef] [PubMed] [Google Scholar]
  • Khamdamov, S-J, D Akramova, S Kuranbaeva, U Shamsieva, Y Musaeva, and S Kalandarova. 2023. “The Role of Vascular Factors in Parkinson’s Disease and Vascular Parkinsonism.” Parkinsonism & Related Disorders 113. [Google Scholar]
  • Korczyn, Amos D. 2015. “Vascular Parkinsonism—Characteristics, Pathogenesis and Treatment.”Nature Reviews Neurology 11 (6): 319–26. [Google Scholar]
  • Thanvi, Bhomraj, Nelson Lo, and Tom Robinson. 2005. “Vascular Parkinsonism—an Important Cause of Parkinsonism in Older People.” Age and Ageing 34 (2): 114–19. [CrossRef] [PubMed] [Google Scholar]
  • Kalra, Seema, Donald G Grosset, and Hani T S Benamer. 2010. “Differentiating Vascular Parkinsonism from Idiopathic Parkinson’s Disease: A Systematic Review.” Movement Disorders 25 (2): 149–56. [CrossRef] [PubMed] [Google Scholar]
  • Goetz, Christopher G, Murat Emre, and Bruno Dubois. 2008. “Parkinson’s Disease Dementia: Definitions, Guidelines, and Research Perspectives in Diagnosis.” Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 64 (S2): S81–92. [Google Scholar]
  • Rolinski, Michal, Chris Fox, Ian Maidment, and Rupert McShane. 2012. “Cholinesterase Inhibitors for Dementia with Lewy Bodies, Parkinson’s Disease Dementia and Cognitive Impairment in Parkinson’s Disease.” Cochrane Database of Systematic Reviews, no. 3. [Google Scholar]
  • Archibald, Neil K, Mike P Clarke, Urs P Mosimann, and David J Burn. 2011. “Visual Symptoms in Parkinson’s Disease and Parkinson’s Disease Dementia.” Movement Disorders 26 (13): 2387–95. [CrossRef] [PubMed] [Google Scholar]
  • Gratwicke, James, Marjan Jahanshahi, and Thomas Foltynie. 2015. “Parkinson’s Disease Dementia: A Neural Networks Perspective.” Brain 138 (6): 1454–76. [CrossRef] [PubMed] [Google Scholar]
  • Galvin, James E, Jori Pollack, and John C Morris. 2006. “Clinical Phenotype of Parkinson Disease Dementia.” Neurology 67 (9): 1605–11. [CrossRef] [PubMed] [Google Scholar]
  • Sharma, Kanishk Deep, Tony Colangelo, and Aaron Mills. 2022. “Trazodone-Induced Parkinsonism: A Case Report.” International Journal of Clinical Pharmacology and Therapeutics 60 (4): 184–87. [CrossRef] [PubMed] [Google Scholar]
  • Morabito, Brianna D, and Barbara Paulison. 2017. “Drug-Induced Parkinsonism: A Case Report.” The Mental Health Clinician 7 (2): 65–68. [CrossRef] [PubMed] [Google Scholar]
  • Akbar, Umer, Duk Soo Kim, and Joseph H Friedman. 2020. “Valbenazine-Induced Parkinsonism.” Parkinsonism & Related Disorders. England. [Google Scholar]
  • Yoo, Ho Sang, Yong Wook Kim, and Na Young Kim. 2019. “Drug-Induced Parkinsonism Manifesting as Gait Freezing in a Patient With Traumatic Brain Injury: A Case Report.” ClinicalNeuropharmacology 42(3):94–96. [Google Scholar]
  • Ak, Sertaç, and A Elif Anıl Yağcıoğlu. 2014. “Escitalopram-Induced Parkinsonism.” General Hospital Psychiatry 36 (1): 126.e1-2. [CrossRef] [PubMed] [Google Scholar]
  • Singh, Ranbir. 2018. “Tramadol-Induced Parkinsonism: A Case Report of a 75-Year-Old Woman.” Journal of Basic and Clinical Physiology and Pharmacology 30 (2): 275–78. [Google Scholar]
  • Kunieda, Kenjiro, Yuichi Hayashi, Megumi Yamada, Shohei Nishida, Ryusuke Moribayashi, Tomohisa Ohno, Ichiro Fujishima, Akio Kimura, and Takayoshi Shimohata. 2023. “The Evaluation of Benzodiazepine-Induced Dysphagia Using High-Resolution Manometry: A CaseReport.” InternalMedicine (Tokyo, Japan), April. [Google Scholar]
  • Undeberg, Megan R, Kimberly C McKeirnan, and David Easley. 2022. “Respecting the Patient’s Choice: A Case of Possible Drug-Induced Parkinsonism.” Pharmacy (Basel, Switzerland). Switzerland. [Google Scholar]
  • Miletić, Vladimir, and Maja Relja. 2011. “Citalopram-Induced Parkinsonian Syndrome: Case Report.” Clinical Neuropharmacology 34 (2): 92–93. [CrossRef] [PubMed] [Google Scholar]
  • Diaz-Segarra, Nicole, Arline Edmond, and Peter Yonclas. 2021. “Functional Improvement of Tacrolimus-Induced Parkinsonism with Amantadine After Liver Transplantation: A Case Report.” Clinical Neuropharmacology 44 (4): 141–44. [CrossRef] [PubMed] [Google Scholar]
  • Gmitterová, Karin, Michal Minár, Miroslav Žigrai, Zuzana Košutzká, Alice Kušnírová, and Peter Valkovič. 2018. “Tacrolimus-Induced Parkinsonism in a Patient after Liver Transplantation-Case Report.” BMC Neurology 18 (1): [CrossRef] [Google Scholar]
  • De Masi R, Orlando S, Toni V, Costa MC. Fluphenazine-Induced Neurotoxicity with Acute Almost Transient Parkinsonism and Permanent Memory Loss: Lessons from a Case Report. International Journal of Molecular Sciences. 2023 Feb 3;24(3):2968. [CrossRef] [PubMed] [Google Scholar]
  • Idiculla, Pretty Sara, Syed Taimour Hussain, and Junaid Habib Siddiqui. 2021. “A Case of Drug- Induced Parkinsonism and Tardive Akathisia with E1143g Polymerase γ Mutation-Innocent Bystander or a Culprit?” Journal of Clinical and Translational Research. Singapore. [PubMed] [Google Scholar]
  • Lima, Marco A, Simone Maradei, and Pericles Maranhao Filho. 2009. “Cyclosporine-Induced Parkinsonism.” Journal of Neurology. Germany. https://doi.org/10.1007/s00415-009-0137-6. [Google Scholar]
  • Kim, Jin-Hyuck, Jaeseol Park, Kyung-Ho Yu, Hyeo-Il Ma, Byung-Chul Lee, Imyel Kim, and Yun Joong Kim. 2012. “Prodromal Dementia with Lewy Bodies Manifesting as Sertraline- Induced Parkinsonism: A Case Report.” Alzheimer Disease and Associated Disorders 26 (2): 191–93. [CrossRef] [PubMed] [Google Scholar]
  • Pasquier de Franclieu, S, C Germain, and F Petitjean. 2009. “[Aripiprazole induced Parkinsonism: A case report].” L’Encephale 35 (5): 496–98. [CrossRef] [Google Scholar]
  • Randhawa, Jaskaren, and Raja Mehanna. 2019. “Drug Induced Parkinsonism: Symptomatic beyond 22 Months.” Parkinsonism & Related Disorders. England. https://doi.org/10.1016/j.parkreldis.2019.08.009. [Google Scholar]
  • Ak S, Yağcıoğlu AE. Escitalopram-induced parkinsonism. General hospital psychiatry. 2014 Jan 1;36(1):126-e1. [Google Scholar]
  • Miletic, Vladimir, and Maja Relja. 2011. “Citalopram-Induced Parkinsonian Syndrome: Case Report.” ClinicalNeuropharmacology 34 (2). [Google Scholar]
  • Perez Lloret, Santiago, Mariela Amaya, and Marcelo Merello. 2009. “Pregabalin-Induced Parkinsonism: A Case Report.” Clinical Neuropharmacology 32 (6). [Google Scholar]
  • Singh, S., Kumar, V., Romero, R., Sharma, K. and Singh, J., 2019. Applications of nanoparticles in wastewater treatment. Nanobiotechnology in bioformulations, pp.395-418. [Google Scholar]
  • Chong, L., Ramakrishna, S. and Singh, S., 2018. A review of digital manufacturing-based hybrid additive manufacturing processes. The International Journal of Advanced Manufacturing Technology, 95, pp.2281-2300. [CrossRef] [Google Scholar]
  • Kumar, D., Agarwal, G., Tripathi, B., Vyas, D. and Kulshrestha, V., 2009. Characterization of PbS nanoparticles synthesized by chemical bath deposition. Journal of Alloys and Compounds, 484(1-2), pp.463-466. [CrossRef] [Google Scholar]
  • Singh, P.S., Singh, T. and Kaur, P., 2008. Variation of energy absorption buildup factors with incident photon energy and penetration depth for some commonly used solvents. Annals of Nuclear Energy, 35(6), pp.1093-1097. [CrossRef] [Google Scholar]
  • Ong, K.L., Stafford, L.K., McLaughlin, S.A., Boyko, E.J., Vollset, S.E., Smith, A.E., Dalton, B.E., Duprey, J., Cruz, J.A., Hagins, H. and Lindstedt, P.A., 2023. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.